Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3513-3516

  Kacar, S ^a,d   Gurkan, A ^b   Karaca, C ^c   Varlsuha, C ^c   Tilif, S ^b  

^a KENT HOSPITAL   (Turkey)

^b Gaziosmanpasa Hospital   (Turkey)

^c Tepecik Training and Research Hospital   (Turkey)

^d Gaziosmanpaa Hastanesi Istanbul ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CREATININE; CYCLOSPORIN A; ENALAPRIL; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; HYPOVOLEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADULT; BIOLOGICAL MARKERS; CALCINEURIN; CREATININE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; SIROLIMUS; TACROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TURKEY; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 78649470203     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.08.043     Document Type: Article

References (32)

1. J. Moro, L. Almenar, and L. Martínez-Dolz mTOR inhibitors: do they help preserve renal function? Transplant Proc 39 2007 2135
2. J. Lidenfeld, G.G. Miller, and S.F. Shakar Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs Circulation 110 2004 3858
3. B.J. Nankivell, R.J. Borrows, and C.L.-S. Fung Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology Transplantation 78 2004 557
4. B.J. Nankivell, R.J. Borrows, and B. Chir The natural history of chronic allograft nephropathy N Engl J Med 349 2003 2326
5. P. Stratta, C. Canavese, and M. Quaglia Post-transplantation chronic renal damage in nonrenal transplant recipients Kidney Int 68 2005 1453
6. J. Morales, A. Fierro, and D. Benavente Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria Transplant Proc 39 2007 591
7. E. Letavernier, and C. Legendre mToR inhibitors-induced proteinuria: mechanisms, significance, and management Transplant Rev 22 2008 125
8. S. Hariharan, M.A. McBride, and W.S. Cherikh Post-transplant renal function in the first year predicts long-term kidney transplant survival Kidney Int 62 2002 311
9. G. Opelz, T. Wujciak, and E. Ritz Association of chronic kidney graft failure with recipient blood pressure Collaborative Transplant Study Kidney Int 53 1998 217
10. T.S. Larson, P.G. Dean, and M.D. Stegall Complete avoidance of calcineurin inhibitors in-renal transplantation: a randomized trial comparing sirolimus and tacrolimus Am J Transplant 6 2006 514
11. E. Letavernier, M.N. Peraldi, and A. Pariente Proteinuria following a switch from calcineurin inhibitors to sirolimus Transplantation 80 2005 1198
12. V. Bumbea, N. Kamar, and D. Ribes Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus Nephrol Dial Transplant 20 2005 2517
13. J.J. Sennesael, J.L. Bosmans, and J.P. Bogers Conversion from cyclosporine to sirolimus in stable renal transplant recipients Transplantation 80 2005 1578
14. J. Radermacher, M. Mengel, and S. Ellis The renal arterial resistance index and renal allograft survival N Engl J Med 349 2003 115
15. M. Boratynska, M. Banasik, and E. Watorek Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients Transplant Proc 38 2006 101
16. L. Straathof-Galena, J.F. Wetzels, and H.B. Dijkman Sirolimus associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism Am J Transplant 6 2006 429
17. E. Morelon, and H. Kreis Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience Transplant Proc 35 3 suppl 2003 52
18. C.G. Groth, L. Backman, and J.M. Morales Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine Sirolimus European Renal Transplant Study Group Transplantation 67 1999 1036
19. H. Kreis, J.M. Cisterne, and W. Land Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients Transplantation 69 2000 1252
20. H.U. Meier-Kriesche, J.D. Schold, and T.R. Srinivas Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus Am J Transplant 5 2005 2273
21. B.D. Kahan, J. Podbielski, and K.L. Napoli Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation Transplantation 66 1998 1040
22. S. Vitko, Z. Wlodarczyk, and L. Kyllnen Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study Am J Transplant 6 2006 531
23. T.R. Srinivas, and H.U. Meier-Kriesche Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result Clin J Am Soc Nephrol 3 suppl 2 2008 S101
24. V.C. McAlister, Z. Gao, and K. Peltekian Sirolimus-tacrolimus combination immunosuppression Lancet 355 2000 376
25. Hartwig T, Pridoehl O, Witzigmann H,, et al. Low-dose sirolimus and tacrolimus in kidney transplantation: first results of a single center experience. Transplant Proc 33:3226, 200
26. F. Diekmann, K. Budde, and F. Oppenheimer Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction Am J Transplant 4 2004 1869
27. A. Grkan, S. Kaar, and U. Erdodu The effect of sirolimus in the development of chronic allograft nephropathy Transplant Proc 40 2008 114
28. C. Legendre, Y. Brault, and J.M. Morales Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years Clin Transplant 21 2007 330
29. Kahan BD for the Rapamune US Study Group Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: a phase III US multicentral trial Lancet 356 2000 194
30. A.S. MacDonald Rapamune Global Study Group A world wide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 27;71 2001 271
31. H.P. Marti, and F.J. Frey Nephrotoxicity of rapamycin: an emerging problem in clinical practice Nephrol Dial Transplant 20 2005 13
32. S. Hiremath, D. Fergusson, and S. Doucette Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence Am J Transplant 7 2007 2350